A case study in generic drug use: should there be risk adjustment in incentive payments for the use of generic medications?

摘要

Payers wishing to promote generic substitution should incorporate the potential for substitution of clinically appropriate generic medications as part of incentives for generic utilization to avoid unintended consequences of using a fixed target rate. A practical methodology for determining an MGR is offered.